Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 4

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part II, Item 2
Chunk 4
---
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES

None. 

ITEM 4.    MINE SAFETY DISCLOSURES

Not Applicable. 

ITEM 5.    OTHER INFORMATION

(c) Trading Plans

During the quarter ended June 30, 2025, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement. 

36

ITEM 6.    EXHIBITS

ExhibitNumberDocument Description3.1Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.3 of the Company’s Form 8-K filed on April 6, 2016)3.2Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (incorporated by reference from Exhibit 3.2 of the Company’s Form 10-Q filed on May 2, 2023)3.3Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023 (incorporated by reference from Exhibit 3.3 of the Company’s Form 10-Q filed on May 2, 2023)10.1Severance and Change of Control Agreement by and between Company and Christopher Anzalone, dated May 9, 2025 (incorporated by reference from Exhibit 10.1 of the Company’s Form 10-Q filed on May 12, 2025)10.2Severance and Change of Control Agreement by and between Company and Daniel Apel, dated May 8, 2025 (incorporated by reference from Exhibit 10.2 of the Company’s Form 10-Q filed on May 12, 2025)10.3Severance and Change of Control Agreement by and between Company and Patrick O'Brien, dated May 9, 2025 (incorporated by reference from Exhibit 10.3 of the Company’s Form 10-Q filed on May 12, 2025)10.4Severance and Change of Control Agreement by and between Company and James Hamilton, dated May 8, 2025 (inc